Dateline City:
BOSTON
Merck Plans to Initiate Phase 2 C-CREST Program to Evaluate Mercks Triple Combination of Grazoprevir/Elbasvir with MK-3682 (formerly IDX21437), a Novel Nucleotide Inhibitor, in Q1 2015
BOSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced the presentation of interim data from the C-SWIFT study
exploring the potential of a candidate triple-therapy regimen consisting
of the fixed-dose combination of grazoprevir/elbasvir (MK-5172/MK-8742,
MK-5172A), the companys investigational NS3/4A protease inhibitor and
NS5A inhibitor, in combination with sofosbuvir, a nucleotide (NS5B)
inhibitor for the treatment of chronic hepatitis C virus (HCV)
infection.
Language:
English
Contact:
MerckMedia:Pam Eisele, 267-305-3558orSarra Herzog, 201-669-6570orInvestor:Joe Romanelli, 908-423-5185orJustin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more